Protagonist Therapeutics, Inc. CEO's Stock Sale

On February 19th, the CEO of Protagonist Therapeutics, Inc. (NASDAQ:PTGX), Dr. Dinesh V. Patel, sold 5,359 shares of the company’s stock. This transaction was executed at an average price of $38.18 per share, resulting in a total sale valuation of $204,606.62. Post-transaction, Dr. Patel holds 540,260 shares in Protagonist Therapeutics, amounting to approximately $20,627,126.80 in value. This sale represents a 0.98% decrease in Dr. Patel's ownership stake in the company. The details of this stock sale were disclosed in a filing with the SEC.

Protagonist Therapeutics Stock Performance

On Thursday, February 20th, shares of Protagonist Therapeutics experienced a slight decline of $0.04, which brought the trading price to $38.49. During this trading session, 618,655 shares changed hands, surpassing the average trading volume of 552,820 shares. The company's 50-day moving average stood at $38.45, while the 200-day average was at $41.85. Over the past year, the stock reached a low of $24.22 and a high of $48.89. Currently, Protagonist Therapeutics has a market capitalization of $2.29 billion, a price-to-earnings (PE) ratio of 14.47, and a beta of 2.22, indicating higher volatility compared to the market.

Brokerage Insights

Recently, various brokerage firms have provided updates on Protagonist Therapeutics’ stock. On February 4th, JPMorgan Chase & Co. increased their price target for the stock from $51.00 to $53.00, maintaining an